Esculin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB13155 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 15 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | amenorrhea (disease) | KG + DL |
| 2 | obsolete hyperuricemia (disease) | KG + DL |
| 3 | Leydig cell hypoplasia due to LH resistance | KG + DL |
| 4 | 46,XY disorder of sex development due to impaired androgen production | KG + DL |
| 5 | hypoxanthine guanine phosphoribosyltransferase partial deficiency | KG + DL |
| 6 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 7 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 8 | hypouricemia, renal | KG + DL |
| 9 | hypogonadotropic hypogonadism with or without anosmia | KG + DL |
| 10 | diabetic nephropathy | KG + DL |
| 11 | plexiform neurofibroma (disease) | KG + DL |
| 12 | breast fibrocystic disease | KG + DL |
| 13 | prostate cancer/brain cancer susceptibility | KG + DL |
| 14 | Brenner tumor | KG + DL |
| 15 | benign reproductive system neoplasm | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.